Advertisement

Tumor Biology

, Volume 34, Issue 5, pp 3035–3039 | Cite as

Myeloperoxidase G463A polymorphism and lung cancer risk in Asians: a pooled analysis

  • Yi-yong Zhou
  • Shao-ming Zhang
  • Zhi-gang Cai
  • Heng Zhang
  • Lei Wang
  • Xiao-ping Xu
  • Hai-bo Wu
Research Article

Abstract

Myeloperoxidase (MPO) is an endogenous oxidant enzyme and can generate reactive oxygen species. The MPO G463A polymorphism influences MPO transcription levels and has been proposed to be associated with risk of lung cancer. To assess the effect of MPO G463A polymorphism on lung cancer risk in Asians, a pooled analysis of published case–control studies was performed. PubMed, Embase, China Biomedical Literature, and Wanfang Medicine databases were searched for eligible studies. The strength of the association between MPO G463A polymorphism and lung cancer risk was measured by odds ratio (OR) with 95 % confidence interval (95% CI). Finally, eight studies with a total of 1,679 lung cancer cases and 1,876 non-cancer controls were included. Overall, MPO G463A polymorphism was associated with decreased risk of lung cancer risk in Asians under two genetic models (OR AA vs. GG = 0.58, 95% CI 0.36–0.96, P = 0.033; OR AA vs. GG+AG = 0.60, 95% CI 0.37–0.98, P = 0.040). There was no obvious risk of publication bias in this meta-analysis. In conclusion, the pooled analysis suggests that MPO G463A polymorphism is associated with decreased risk of lung cancer risk in Asians.

Keywords

Myeloperoxidase Polymorphism Lung cancer 

Notes

Conflicts of interest

None

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.CrossRefPubMedGoogle Scholar
  3. 3.
    Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–80.CrossRefPubMedGoogle Scholar
  4. 4.
    Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. Lancet Oncol. 2011;12:399–408.CrossRefPubMedGoogle Scholar
  5. 5.
    Chu H, Wang M, Gu D, Wu D, Zhang Z, Tang J. The MPO –463G>A polymorphism and cancer risk: a meta-analysis based on 43 case–control studies. Mutagenesis. 2010;25:389–95.CrossRefPubMedGoogle Scholar
  6. 6.
    Zamocky M, Gasselhuber B, Furtmuller PG, Obinger C. Molecular evolution of hydrogen peroxide degrading enzymes. Arch Biochem Biophys. 2012;525:131–44.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Wenten M, Gauderman WJ, Berhane K, Lin PC, Peters J, Gilliland FD. Functional variants in the catalase and myeloperoxidase genes, ambient air pollution, and respiratory-related school absences: an example of epistasis in gene–environment interactions. Am J Epidemiol. 2009;170:1494–501.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Wainstein RV, Wainstein MV, Ribeiro JP, Dornelles LV, Tozzati P, Ashton-Prolla P, et al. Association between myeloperoxidase polymorphisms and its plasma levels with severity of coronary artery disease. Clin Biochem. 2010;43:57–62.CrossRefPubMedGoogle Scholar
  9. 9.
    Garrity-Park M, Loftus Jr EV, Sandborn WJ, Smyrk TC. Myeloperoxidase immunohistochemistry as a measure of disease activity in ulcerative colitis: association with ulcerative colitis-colorectal cancer, tumor necrosis factor polymorphism and RUNX3 methylation. Inflamm Bowel Dis. 2012;18:275–83.CrossRefPubMedGoogle Scholar
  10. 10.
    Yuzhalin AE, Kutikhin AG. Inherited variations in the SOD and GPX gene families and cancer risk. Free Radic Res. 2012;46:581–99.CrossRefPubMedGoogle Scholar
  11. 11.
    Jiang Z, Zhang Z, Wang Z, Zhang G, Hu K, He B, et al. Association of the 463G-A myeloperoxidase gene polymorphism with gastric cancer risk. Hepatogastroenterology. 2012;59:757–61.PubMedGoogle Scholar
  12. 12.
    Pabalan N, Jarjanazi H, Sung L, Li H, Ozcelik H. Menopausal status modifies breast cancer risk associated with the myeloperoxidase (MPO) G463A polymorphism in caucasian women: a meta-analysis. PLoS One. 2012;7:e32389.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Lu W, Xing D, Qi J, Tan W, Miao X, Lin D. Genetic polymorphism in myeloperoxidase but not GSTM1 is associated with risk of lung squamous cell carcinoma in a Chinese population. Int J Cancer. 2002;102:275–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Wu XM, Zhou YK, Ren S, Hao QL. Gene polymorphism of myeloperoxidase and genetic susceptibility to lung cancer. Ai Zheng. 2003;22:912–5.PubMedGoogle Scholar
  15. 15.
    Chan EC, Lam SY, Fu KH, Kwong YL. Polymorphisms of the GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the CDKN2A and RARB genes. Cancer Genet Cytogenet. 2005;162:10–20.CrossRefPubMedGoogle Scholar
  16. 16.
    Park JH, Park JM, Kim EJ, Cha SI, Lee EB, Kim CH, et al. Myeloperoxidase −463G>A polymorphism and risk of primary lung cancer in a Korean population. Cancer Detect Prev. 2006;30:257–61.CrossRefPubMedGoogle Scholar
  17. 17.
    Yang M, Choi Y, Hwangbo B, Lee JS. Combined effects of genetic polymorphisms in six selected genes on lung cancer susceptibility. Lung Cancer. 2007;57:135–42.CrossRefPubMedGoogle Scholar
  18. 18.
    Yoon KA, Kim JH, Gil HJ, Hwang H, Hwangbo B, Lee JS. Cyp1b1, CYP1A1, MPO, and GSTP1 polymorphisms and lung cancer risk in never-smoking Korean women. Lung Cancer. 2008;60:40–6.CrossRefPubMedGoogle Scholar
  19. 19.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  20. 20.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  21. 21.
    Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRefGoogle Scholar
  22. 22.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Le Marchand L, Seifried A, Lum A, Wilkens LR. Association of the myeloperoxidase −463G–>A polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9:181–4.PubMedGoogle Scholar
  24. 24.
    Zhang TY, Hong XT, Wu YJ, Wu YM. Myeloperoxidase polymorphism in lung cancer patients of Henan Han population. J Zhengzhou Univ (Med Sci). 2006;42:448–50.Google Scholar
  25. 25.
    Xiao XY, Wang XD, Zang DY. MMP1-1607 1G/2G polymorphism and lung cancer risk: a meta-analysis. Tumour Biol. 2012;33:2385–92.CrossRefPubMedGoogle Scholar
  26. 26.
    Hu C, Wang J, Xu Y, Li X, Chen H, Bunjhoo H, et al. Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysis. Gene. 2013;517:65–71.CrossRefPubMedGoogle Scholar
  27. 27.
    Wang S, Zhu J, Zhang R, Gu Z. Association between microsomal epoxide hydrolase 1 T113C polymorphism and susceptibility to lung cancer. Tumour Biol. 2013;34:1045–52.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Yi-yong Zhou
    • 1
  • Shao-ming Zhang
    • 1
  • Zhi-gang Cai
    • 1
  • Heng Zhang
    • 1
  • Lei Wang
    • 1
  • Xiao-ping Xu
    • 1
  • Hai-bo Wu
    • 1
  1. 1.Thoracic Tumor CenterPeople’s Liberation Army 455 HospitalShanghaiChina

Personalised recommendations